Study finds significant variation in biomarker test utilization and treatment for non–small-cell lung cancer
Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in
The
Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients.
Using exploratory data analysis and process-mining techniques in a real-world setting, investigators identified significant variation in test utilization and treatment. They also found that while whole-genome sequencing, in which a patient s unique DNA is mapped at once, may not be a cost saving alternative to biomarker testing, as some have suggested, it may have other benefits for patients, such as decreasing the time between testing and therapy
E-Mail
IMAGE: The tests are ordered chronologically. Each row represents the biomarker test combination for one patient. Numbers shown on the right indicate the number of patients who received the same biomarker. view more
Credit: van de Ven, Michiel, et al.
Philadelphia, March 15, 2021 - Biomarker testing surveys specific disease-associated molecules to predict treatment response and disease progression; however its use has complicated the diagnosis of non-small-cell lung cancer (NSCLC). In a new study in
The Journal of Molecular Diagnosis, published by Elsevier, investigators provide for the first time a complete overview of biomarker testing, spanning multiple treatment lines, in a single cohort of patients.
US biotechnology firm Illumina is collaborating with the University of Melbourne and the Victorian Government to set up a A$60 million Genomics Hub in.